NCT04676373View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions

Pompe's Disease

Interventions

DRUG

ALGLUCOSIDASE ALFA

"Pharmaceutical form:solution for infusion~Route of administration: intravenous"

Trial Locations (1)

Unknown

Investigational Site, China

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT04676373 - Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen | Biotech Hunter | Biotech Hunter